Drugs / NT-112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06218914 | Mar 2024 → Aug 2027 expected | colorectal carcinoma, endometrial cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NT-112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06218914 ↗ |
| Modality | Cell therapy | “Autologous, engineered T Cells” NCT06218914 ↗ |
| Target | KRAS | “NT-112 targets KRAS G12D” NCT06218914 ↗ |